89
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar

, &
Pages 41-46 | Published online: 31 Jan 2018

References

  • MooreHCdeKNKeilADUse of data linkage to investigate the aetiology of acute lower respiratory infection hospitalisations in childrenJ Paediatr Child Health201248652052822077532
  • GlezenWATaberLLFrankALKaselJARisk of primary infection and reinfection with respiratory syncytial virusAm J Dis Child1996140543546
  • ProberCGWangEEReducing the morbidity of lower respiratory tract infections caused by respiratory syncytial virus: still no answerPediatrics19979934724759041306
  • SimoesEASondheimerHMTopFHJrRespiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study GroupJ Pediatr199813344924999787686
  • Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and NewbornPediatrics19981025121112169794957
  • The IMpact-RSV Study GroupPalivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infantsPediatrics19981023531537
  • FeltesTFCabalkaAKMeissnerHCPalivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseJ Pediatr2003143453254014571236
  • RomeroJRPalivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usagePediatr Infect Dis J2003222S46S5412671452
  • PaesBMitchellILiAHarimotoTLanctotKLRespiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005–2012) compared to other international registriesClin Dev Immunol2013201391706823861694
  • Centers for Disease Control and PreventionRespiratory syncytial virus activity – United States, July 2007–December 2008MMWR Morb Mortal Wkly Rep200857501355135819092759
  • WahabAA·DawodST·RamanHMClinical characteristics of respiratory syncytial virus infection in hospitalized healthy infants and young children in QatarJ Trop Pediatr200147636336611827306
  • American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines CommitteeUpdated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infectionPediatrics2014134241542025070315
  • Committee on Infectious DiseasesFrom the American Academy of Pediatrics: Policy statements – Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infectionsPediatrics200912461694170119736258
  • JobeAHBancalariENICHD/NHLBI/ORD workshop summary: bronchopulmonardysplasiaAm J Respir Crit Care Med20011631723172911401896
  • ParnesCGuillerminJHabersangRPalivizumab Outcomes Registry Study GroupPalivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: results from the palivizumab outcomes registryPediatr Pulmonol200335648448912746948
  • HenckelELuthanderJBerggrenEPalivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002Pediatr Infect Dis J2004231273114743042
  • DuppenthalerAGorgievski-HrisohoMAebiCRegional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infantsSwiss Med Wkly200113111–1214615111416887
  • Carbonell-EstranyXQueroJHospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasonsPediatr Infect Dis J200120987487911734767
  • GrimaldiMGouyonBSagotPQuantinCHuetFGouyonJBPalivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasiaPediatr Pulmonol200742318919217243184
  • AndabakaTNickersonJWRojas-ReyesMXRuedaJDBacic VrcaVBarsicBMonoclonal antibody for reducing the risk of respiratory syncytial virus infection in childrenCochrane Database Syst Rev20134CD00660223633336